The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer

Table 2 Cox-regression analyses considering BRFS

	p value
Patient and treatment related parameters
iPSA in ng/ml (< 10, 10–20, > 20)	0.314
Gleason score in biopsy (< 7, 7, or > 7)	0.018
clinical T stage (2a + b, 2c, 3)	0.031
Volume DIL-imaging (continuous)	0.034
Age in years (continious)	0.773
Usage of ADT	0.223
Prescription dose in Gy (continious)	0.374
RT technique (3D, IMRT)	0.271

Results of the Cox regression analyses for the influence of different patient, treatment and dose parameters on the BRFS. Cut-off values for respective dose parameters were determined by an explorative analysis. None of the Dmin values were significant in PG and SPG, respectively. None of the binarized Dmean values were significant in any of the three volumes. Gleason score and cT stage were not significant (p < 0.05) in any of the multivariate analyses including dose parameters. Abbreviations: CI confidence interval, HR hazard ratio. Bold = values with p < 0.05

ISSN: 1748-717X